Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast maintenance of remission after biologics in psoriasis vulgaris
jRCTs031200238Completed
- Sponsor
- Skin Health Institute
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of apremilast in plaque psoriasis and psoriatic arthritis (PsA) (2 arms), sponsored by Skin Health Institute. Primary endpoint: Remission maintenance period. Started Jun 2021; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCTs031200238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200238.